红细胞微粒限制脑出血血肿增长
在大鼠胶原酶诱导的自发性脑出血模型中,高压挤出人红细胞制备的红细胞微粒可限制血肿增长;溶媒组与红细胞微粒组(2.66×10^10 个/kg)血肿体积分别为 143±8 mm³ 和 86±4 mm³;脑出血后 4.5 小时内给药仍可限制血肿体积。
要点
- 红细胞微粒治疗限制自发性脑出血大鼠模型的血肿增长。
- 溶媒组与红细胞微粒组(2.66×10^10 个/kg)血肿体积为 143±8 mm³ 与 86±4 mm³。
- 脑出血后 4.5 小时给予红细胞微粒,血肿体积较对照组低 24%。
核心结论
- 在大鼠模型中,红细胞微粒治疗限制自发性脑出血后血肿增长并改善结局。
- 作者认为红细胞微粒有潜力限制自发性脑出血患者的血肿增长。
研究设计与样本
- 在大鼠中经纹状体内注射胶原酶诱导自发性脑出血。
- 红细胞微粒由人红细胞经高压挤出制备。
- 评估脑出血后行为学及血肿/病灶体积,确定限制血肿增长的最佳剂量、给药方案和治疗时间窗。
- 评估红细胞微粒对脑出血后长期行为学和组织病理学结局的影响。
主要发现
- 红细胞微粒治疗限制自发性脑出血后血肿增长。
- 溶媒组与红细胞微粒组(2.66×10^10 个/kg)的血肿体积分别为 143±8 mm³ 和 86±4 mm³。
- 确定了限制血肿扩大的最佳红细胞微粒给药方案。
- 脑出血后 4.5 小时内给予红细胞微粒仍可限制血肿体积;4.5 小时治疗组血肿体积较对照组低 24%。
- 红细胞微粒治疗还改善脑出血后长期组织病理学和行为学结局。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spontaneous intracerebral hemorrhage (sICH) is the deadliest stroke subtype with no effective therapies. Limiting hematoma expansion is a promising therapeutic approach. Red blood cell-derived microparticles (RMPs) are novel hemostatic agents. Therefore, we studied the potential of RMPs in limiting hematoma growth and improving outcomes post-sICH. METHODS: sICH was induced in rats by intrastriatal injection of collagenase. RMPs were prepared from human RBCs by high-pressure extrusion. Behavioral and hematoma/lesion volume assessment were done post-sICH. The optimal dose, dosing regimen, and therapeutic time window of RMP therapy required to limit hematoma growth post-sICH were determined. We also evaluated the effect of RMPs on long-term behavioral and histopathologic outcomes post-sICH. RESULTS: RMP treatment limited hematoma growth following sICH. Hematoma volume (mm3) for vehicle- and RMP- (2.66×1010 particles/kg) treated group was 143±8 and 86±4, respectively. The optimal RMP dosing regimen that limits hematoma expansion was identified. RMPs limit hematoma volume when administered up to 4.5-hour post-sICH. Hematoma volume in the 4.5-hour post-sICH RMP treatment group was lower by 24% when compared with the control group. RMP treatment also improved long-term histopathologic and behavioral outcomes post-sICH. CONCLUSIONS: Our results demonstrate that RMP therapy limits hematoma growth and improves outcomes post-sICH in a rodent model. Therefore, RMPs have the potential to limit hematoma growth in sICH patients.
引用
- Rehni AK, Cho S, Quero HN, et al. Red Blood Cell Microparticles Limit Hematoma Growth in Intracerebral Hemorrhage. Stroke. 2022. PMID: 36069183. doi:10.1161/STROKEAHA.122.039641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。